Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ciliatech receives FDA IDE approval to initiate US feasibility study of INTERCIL

9 September 2026 · By · Wire by Fusion42

Published

9 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at med-techinsights.com →

◆ Verified

Fusion42 · 9 September 2026 · Fusion42 review

Ciliatech received FDA IDE approval to start a US feasibility study for its INTERCIL glaucoma implant, aiming to enroll 30 patients to evaluate safety and performance. This milestone advances US clinical data generation and regulatory development for a treatment addressing the unmet need between MIGS and filtering surgery.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can now enter the US glaucoma implant market segment that sits between minimally invasive and traditional surgeries. This FDA nod opens the door to prove your device’s clinical value to US regulators and payers faster than starting from scratch.

◆ Coverage

1 source · 9 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfda-ideclinical-trialglaucomamedical-deviceus-market